OKYO News and Press, OKYO Pharma Limited From 10/31/23

2023-10-31 13:18:43 ET More on OKYO Pharma OKYO shares retreat 12% after rallying ahead of Phase 2 study update OKYO Pharma announces capital raise of $3.95M without any underwriter or agent Financial information for OKYO Pharma For further details see: O...

Pricing of a registered direct offering for $1.64M of 1,092,600 ordinary shares at an offering price of $1.50 per ordinary share Simultaneous extinguishment of $4.20M of payables by issuing 2,766,667 ordinary shares, at the offering price of $1.50 per ordinary share, m...

OKYO plans to initiate a 40-patient OK-101 open-label clinical trial in Q1 2024 with Dr Pedram Hamrah, Tufts Medical Center, as Principal Investigator, a leading expert in treating patients with NCP. Second clinical indication for OK-101 which is currently in 240-patient Phase 2 clini...

2023-10-06 08:53:38 ET OMNIQ ( OMQS ) -44% announces pricing of public offering. Wheeler Real Estate Investment Trust  ( WHLR ) -21% . ShiftPixy  ( PIXY ) -19% . Nanobiotix  ( NBTX ) -15% . Aehr Test ( AEHR ) -11% . ...

2023-10-05 11:53:30 ET More on OKYO Pharma OKYO Pharma announces capital raise of $3.95M without any underwriter or agent OKYO Pharma rebounds on withdrawal of equity offering Financial information for OKYO Pharma For further details see: OKYO shares retr...

Over 95% of randomized DED patients have completed 4 weeks of dosing in the planned 12-week Phase 2 trial, with 72% of randomized DED patients completing 8 weeks, and 7.1% of patients completing the entire 12-week trial. The dropout rate is 5.4% and unrelated to side effects. Top-...

2023-09-15 08:14:04 ET More on pre-market losers stock: Compare metrics for AXLA to HNST, SLE Honest Company: Honestly Bad Economics The Honest Company: Very Few Options The Honest Company, Inc. ( HNST ) Q2 2023 Earnings Call Transcript The Honest...

LONDON and NEW YORK, Sept. 15, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (“DED”), today announced the clos...

2023-09-14 11:03:38 ET More on OKYO Pharma Seeking Alpha’s Quant Rating on OKYO Pharma Historical earnings data for OKYO Pharma Financial information for OKYO Pharma OKYO Pharma rebounds on withdrawal of equity offering For further details see:...

2023-09-14 10:00:06 ET More on Health Care Select Sector SPDR Seeking Alpha’s Quant Rating on Health Care Select Sector SPDR Dividend scorecard for Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare ( XLV ) ...